Archive

August 2025

Browsing

The surge in energy-intensive artificial intelligence (AI) applications is driving renewed investment and policy focus on nuclear power.

Nuclear fusion is a re-emerging cornerstone technology that could meet the twin challenges of decarbonizing the global economy while energizing the data centers needed to power the AI revolution.

Nuclear power offers a 24/7, carbon-free source of baseload electricity. Unlike intermittent clean energy sources like wind and solar, nuclear plants also require significantly less land and fewer raw materials per unit of energy, adding to their appeal.

The advantages presented by nuclear power position it as a compelling opportunity for investors looking to capitalize on the future of global energy innovation.

SMRs: The new face of nuclear

Small modular reactors (SMRs), a broad classification that covers several designs, are helping to transform the nuclear sector. Smaller than traditional reactors at a capacity of 300 megawatts electrical (MWe) or less, SMRs can be factory built with enhanced safety features and lower upfront capital costs.

For example, NuScale Power’s (NYSE:SMR) recently approved US460 SMR has passive safety features. Unlike large nuclear plants that require active cooling systems, its design uses natural forces like gravity and convection for automatic shutdown and cooling, removing the need for operator intervention or external power in emergencies.

Similarly, X-Energy’s flagship Xe-100 SMR uses proprietary TRISO-X fuel, which is designed with multiple layers of ceramic materials that cannot melt, even at extremely high temperatures. The fuel serves as the primary containment barrier, ensuring safety without active intervention. In early August, X-Energy selected Clark Construction Group to finish the building construction phase of its advanced nuclear fuel fabrication facility.

Kairos Power is also making headway with its advanced modular reactor design, which combines TRISO fuel with a molten salt cooling system. The installation of the reactor vessel for the company’s third engineering test unit in Tennessee is a key milestone in the buildout of the company’s advanced modular design.

The design of SMRs also enable them to be deployed in a diverse range of locations.

Arc Energy’s sodium-cooled fast reactor is designed to be remote, able to operate for over two decades without refueling. In June, the company signed a memorandum of understanding with energy infrastructure company Deep Atomic to jointly explore deployment opportunities across North America.

Microreactors, a much smaller subcategory of SMRs that typically produce less than 10 MWe of power, represent the next wave of flexibility. Oklo (NYSE:OKLO), an advanced nuclear technology company headquartered in California, recently secured a contract with the US Air Force to pilot a microreactor at Eielson Air Force Base in Alaska.

For its part, BWX Technologies (NYSE:BWXT) has begun fabricating the reactor core for the 1.5 megawatt Pele demonstration microreactor for the US Department of Defense, a project that highlights the military’s growing interest in portable, reliable nuclear power.

Meanwhile, California-based Hadron Energy is developing the Hadron micro modular reactor, a compact nuclear power system designed to deliver about 10 megawatts of power. Using a ceramic core and solid fuel, the patent-pending design is intended for deployment in remote or space-limited locations.

While current reactors use nuclear fission to create heat and generate electricity, nuclear fusion, a separate but similar process that is still in development, is also gaining traction.

The US Department of Energy’s (DOE) Milestone-Based Fusion Development Program was authorized in 2020 and officially launched in September 2022, with eight participants announced in May 2023.

In a webinar, Colleen Nehl of the DOE’s Office of Fusion Energy Sciences, said the eight companies were “making great progress’ and spoke about new opportunities for additional teams to secure program funding.

AI and the coming energy crunch

AI’s voracious appetite for power is forcing tech giants to rethink their energy sourcing strategies. High-performance computing demands not only massive amounts of electricity, but also near-perfect uptime.

As AI models scale and data centers proliferate, the nuclear sector’s ability to deliver constant, emissions-free electricity positions it as a foundational technology for sustainable tech growth.

This has led companies like Microsoft (NASDAQ:MSFT) and Alphabet (NASDAQ:GOOGL) to make landmark investments in nuclear fusion. In 2023, the former announced an agreement to purchase fusion energy from Helion Energy, while the latter signed a 200 megawatt fusion offtake deal with Commonwealth Fusion Systems in June.

Nuclear power can help technology companies sustainably expand their AI capabilities.

In 2024, Microsoft entered a power-purchase deal with Constellation Energy (NASDAQ:CEG) to revive the Three Mile Island nuclear facility, aimed at supporting its burgeoning AI infrastructure.

Additionally, Amazon Web Services (AWS) (NASDAQ:AMZN) committed over US$500 million toward the development of SMRs, including a project with Dominion Energy near its North Anna site, to meet its growing clean-energy demands.

In May, US President DonaldTrump issued an executive order directing the DOE to create a readily available fuel bank with at least 20 metric tons of high-assay low-enriched uranium (HALEU) for authorized advanced nuclear reactor projects, explicitly citing AI and other critical infrastructure as priorities.

HALEU is a specific type of nuclear fuel containing between 5 and 20 percent of the fissile uranium-235 isotope.

Speaking about nuclear energy in a July interview on New York radio station 77 WABC, Lee Zeldin, administrator of the Environmental Protection Agency, told host John Catsimatidis, “As it relates to the Trump administration, while we’re here, we want to do everything in our power to fast-track the process.”

Expedited review timelines from the Nuclear Regulatory Commission for TerraPower’s construction permit for the Kemmerer power station, and the Tennessee Valley Authority’s BWRX-300 reactor at Clinch River came in response to Trump’s executive order.

Managing the nuclear waste challenge

Despite its advantages, nuclear power faces the persistent challenge of disposing of spent nuclear fuel.

Nuclear power’s waste profile varies significantly depending on the technology used.

Traditional fission reactors split heavy atoms such as uranium-235, generating smaller fission products that remain highly radioactive for thousands of years.

This process also produces spent fuel, which must be securely stored and managed over the long term.

By contrast, fusion — the reaction that powers the sun — fuses light atoms like hydrogen isotopes into heavier ones, releasing helium, a non-radioactive gas. The main radioactive byproducts come from reactor components that become activated by high-energy neutrons.

Known as activation waste, these materials typically decay to safe levels within decades to centuries rather than millennia. While fusion waste is less hazardous and easier to handle, it still requires proper management, recycling or disposal.

To be safely disposed of, nuclear waste needs to be isolated from the environment for an extremely long time because many of the radioactive isotopes it contains have very long half-lives. A half-life is the time it takes for half of the radioactive material to decay. For example, plutonium-239 has a half-life of over 24,000 years.

Long-term isolation in a stable, deep geological repository is necessary to prevent this harmful radiation from contaminating the environment and endangering human health.

While the US has implemented some temporary storage solutions, the American Nuclear Society (ANS) and other organizations are advocating for a new program to establish long-term solutions.

The ANS joined seven other organizations to send a letter to US Secretary of Energy Chris Wright on July 8, asking to meet with him to discuss the issue. At the time of this writing, no meeting had been set. The Nuclear Waste Technical Review Board will convene on August 27 to review information on the DOE’s activities to manage spent nuclear fuel and high-level radioactive waste and to receive program updates from the DOE’s Office of Nuclear Energy.

Meanwhile, companies and institutions are discovering innovative solutions.

Deep Isolation is advancing directional borehole drilling, while workers at the DOE’s Savannah River site have developed a new carrier system to speed the processing of spent fuel.

Where is investment flowing?

As nuclear capabilities are built out, capital has been moving into every stage of the value chain.

Waste disposal innovators like Deep Isolation recently closed a reverse merger and an oversubscribed US$33 million private placement financing, a development that signals a potential market for nuclear waste storage solutions.

Meanwhile, the industry is addressing a shortage of domestic reactor fuel with a wave of innovation and new investment from the government and private sector. This is especially true for HALEU, a specialized fuel needed for many advanced reactor designs. The DOE is leading efforts to expand HALEU production, releasing plans to downblend highly enriched uranium (HEU) at the Savannah River site into HALEU.

At the decommissioned Paducah Gaseous Diffusion Plant, the DOE signed a lease with General Matter for a new uranium enrichment facility, while Global Laser Enrichment advanced its separate laser-based enrichment project by completing both its full license application and a safety analysis report for US Nuclear Regulatory Commission review.

The DOE also extended its US$110 million contract with Centrus Energy (NYSE:LEU) for HALEU production and launched its Fuel Line Pilot Program to fast track nuclear fuel fabrication for new test reactors in July.

Other next-generation fuel technologies are also progressing.

TRISO fuel, designed with multiple ceramic layers that prevent melting, remains a focus area. BWX Technologies’ successful testing of a new furnace for additively manufacturing TRISO fuel marked a key milestone in the company’s efforts to build an entirely new industrial supply chain, while Shine Technologies’ fuel recycling venture with Standard Nuclear signals a market for firms focused on recycling spent nuclear fuel to extract more energy.

Beyond advanced reactors, fuel improvements are also advancing. Lightbridge (NASDAQ:LTBR) will soon begin testing its enriched uranium-zirconium alloy fuel at Idaho National Laboratory.

Meanwhile, the High Burnup Experiments in Reactivity-Initiated Accident project completed its first test, aimed at understanding light water reactor fuel performance under extreme conditions.

Looking ahead

The future of nuclear power appears promising.

“Demand has gone from 1 or 2 percent compound annual (growth) to now about 4 percent and possibly even higher. And that doesn’t even include the COP28 goals of tripling nuclear by 2050,” he continued.

Building on burgeoning momentum, the DOE has officially selected 10 companies for its reactor pilot program, with a target of having at least three designs reach criticality outside of laboratories by July 4, 2026.

Given the promising outlook, investors have a compelling opportunity to capitalize on the industry’s future.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

XRP price trades at $3.23 today, August 14, with a 0.53% drop. It has moved above a bullish pennant, a sign that the rally might extend until it reaches $6. Supporting this bullish thesis are whales and the attention that Teucrium’s XXRP ETF is getting. XRP Price Targets Breakout After Bullish Pennant Breakout From July

The post XRP Price Prediction — Pennant Breakout Signals $6 Rally Amid Whale Buying as XXRP ETF Hits $462M appeared first on CoinGape.

Hyperliquid’s AUM has hit a record $6.2 billion, fueled by large inflows of USDC and ETH over the past days. As a result, the HYPE price recorded gains near 5%. Hyperliquid AUM Hits Record $6 Billion Mark According to Dune data, Hyperliquid’s AUM crossed the $6 billion mark due to recent inflows from USDC and

The post Hyperliquid AUM Surpasses $6.2B Amid USDC and ETH Inflows, HYPE Surges appeared first on CoinGape.

The U.S. PPI data have come in way above expectations, rising to as high as 3.3% year-on-year (YoY). This has sparked a bearish sentiment among investors, with the BTC price sharply dropping below $120,000 following the report’s release. U.S. PPI Data Comes In Hot, Leading To BTC Price Crash U.S. Bureau of Labor Statistics data

The post U.S. PPI Data Comes In Hot At 3.3%, BTC Price Crashes appeared first on CoinGape.

U.S. Treasury Secretary Scott Bessent confirmed the nation’s $15–$20 billion Bitcoin reserve and a halt to sales. Bitcoin hit a record $123,360 before retreating. Bessent Signals Strategic Reserve Shift as U.S. Halts Bitcoin Sales, Keeps Gold Policy Unchanged U.S. Treasury Secretary Scott Bessent has confirmed that the government’s Bitcoin reserves are valued between $15 billion

The post Breaking: U.S. Bitcoin Reserves Worth Up To $20 Billion, Scott Bessent Confirms appeared first on CoinGape.

Rare Evo 2025:- The recently concluded Rare Evo multi-day blockchain/Web3 conference in Las Vegas saw many new developers and protocol teams pitching new innovative ideas and applications of blockchain technology. Among these, a project that caught the eyes has been Sandro Gonzalez-led KWARXS project aiming to make solar energy accessible and profitable. Sandro has built

The post Rare Evo 2025: A New Project on Cardano is Putting 5.9 GW of Sunshine on the Blockchain appeared first on CoinGape.

Keith Weiner, founder and CEO of Monetary Metals, discusses gold and silver’s performance so far this year and shares his outlook for the rest of 2025.

He also explains what makes today’s gold bull market different than those seen in prior years.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ.

After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak of 4,954.813 on September 19, 2024. While the index had pulled back to 4,530.69 as of August 5, 2025, further growth could be in store in the future.

According to a Towards Healthcare analyst report, the global biotech market is expected to grow at a compound annual growth rate of 12.5 percent from now to 2034, reaching a valuation of US$5.04 trillion.

Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.

The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.

Data was gathered on August 5, 2025, using TradingView’s stock screener. Small-cap biotech stocks with market caps between US$50 million and US$500 million at that time were considered for this list.

1. Tiziana Life Sciences (NASDAQ:TLSA)

Year-to-date gain: 227.8 percent
Market cap: US$256.36 million
Share price: US$2.26

Tiziana Life Sciences is a clinical-stage biopharma which is developing therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its pipeline of candidates is built on its patent drug delivery technology that provides a possible alternative to intravenous delivery. Tiziana’s lead candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody.

Tiziana Life Sciences shares hit US$1.69 on March 7 after the company filed its investigational new drug application to the US Food and Drug Administration (FDA) for a Phase 2 clinical trial in amyotrophic lateral sclerosis (ALS), which is supported by the ALS Association. However, by early April that value had fallen back to US$0.78 per share.

A series of positive news flow later in the spring helped to give Tiziana shares another boost. In April, John Hopkins University and the University of Massachusetts commenced dosing of the biotech company’s intranasal foralumab in Phase 2 trials for patients with non-active secondary progressive multiple sclerosis. On May 7, the company shared positive results from the use of its lead candidate in improving the quality of life for patients with that form of multiple sclerosis.

Tiziana is also studying the use of intranasal foralumab for treating moderate Alzheimer’s disease. On May 9, it announced that PET scans of a patient with moderate Alzheimer’s showed a significant reduction in microglia activation associated with neuroinflammation after three months of treatment.

Shares of Tiziana reached US$1.62 on May 13.

On July 21, the company announced an ‘unexpected discovery’ in its findings of an immunologic analysis of the patient with Alzheimer’s disease.

‘In an unexpected discovery, the analysis revealed an increase in phagocytosis markers in classical monocytes, suggesting that nasal foralumab may enhance their ability to clear amyloid plaques,’ the press release states. ‘This unexpected effect may open new avenues for treating Alzheimer’s Disease by targeting both inflammation and amyloid accumulation.’

Tiziana’s share price climbed through the remainder of the month, hitting a year-to-date high of US$2.50 on July 31.

2. Palvella Therapeutics (NASDAQ:PVLA)

Year-to-date gain: 224.98 percent
Market cap: US$416.08 million
Share price: US$37.64

Palvella Therapeutics is a clinical-stage biopharma developing treatments targeting rare genetic skin diseases for which there are no FDA-approved therapies. The company’s product pipeline centers on its patented QTORIN platform, which has an initial focus on rare genetic skin diseases.

Its lead product candidate, QTORIN rapamycin, is currently in a Phase 2 clinical trial in cutaneous venous malformations, and a Phase 3 clinical trial in microcystic lymphatic malformations (LM). QTORIN rapamycin has been granted breakthrough therapy designation, orphan drug designation and fast track designation from the FDA for the treatment of microcystic LMs.

After starting the year at US$12.00, shares of Palvella had surged to US$20.99 by February 18. About a week earlier, the company had shared plans to expand the Phase 3 trial to include pediatric patients from three to five years of age. That momentum in Palvella’s share price continued to rally to US$29 per share on March 13.

June produced a number of significant milestones for Palvella. On June 9, the company received initial proceedings from a grant issued by the FDA Office of Orphan Products Development for its Phase 3 trial, and on June 23, it completed enrollment for the trial with 51 subjects, 25 percent over its target. The company closed out the month with news it was added to the broad-market Russell 3000 Index and the Russell 2000 Index.

The company said it remains on track to deliver top-line Phase 3 data in Q1 2026 to support its planned new drug application submission later that year.

While the company didn’t release news in July, Palvella Therapeutics’ share price climbed significantly through the month to hit a year-to-date high of US$39.87 on July 28.

3. OKYO Pharma (NASDAQ:OKYO)

Year-to-date gain: 163.03 percent
Market cap: US$117.35 million
Share price: US$3.13

OKYO Pharma is a clinical-stage biopharma developing therapies for the treatment of neuropathic corneal pain and dry eye disease. Its lead candidate is urcosimod, a non-steroidal anti-inflammatory and non-opioid analgesic.

So far in 2025, the company has achieved multiple milestones related to its Phase 2 trial of urcosimod for treatment of neuropathic corneal pain.

On April 30, OKYO announced plans to end the trial early to analyze the data from the patients who had completed the trial, with the goal of accelerating its clinical development and expanding the program. Supporting the decision was the fact that urcosimod had previously demonstrated safety in OKYO’s completed Phase 2 trial of the candidate to treat patients with dry eye disease.

The next day, news broke that the FDA granted urcosimod fast track designation for the treatment of neuropathic corneal pain. OKYO’s stock price reached US$1.57 on May 1.

On July 17, OKYO posted strong top-line data from its Phase 2 clinical trial, and stated it is planning a meeting with the FDA to discuss next steps for its lead drug candidate. The following day, OKYO received US$1.9 million in non-dilutive funding to support its clinical development of urcosimod.

Shares of OKYO hit a year-to-date high of US$3.17 on August 5.

4. IO Biotech (NASDAQ:IOBT)

Year-to-date gain: 129.47 percent
Market cap: US$144.28 million
Share price: US$2.16

IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating therapeutic cancer vaccines based on its T-win technology platform, designed to activate T cells to target both tumor cells and the immune-suppressive cells. The company’s lead cancer vaccine candidate IO102-IO103, which has the brand name Cylembio, is currently in clinical trials.

The FDA granted breakthrough therapy designation to IO102-IO103 when used in combination with Merck’s (NYSE:MRK) anti-PD-1 therapy KEYTRUDA for the treatment of advanced melanoma based on positive Phase 1/2 first line metastatic melanoma data.

At the start of the year, IO Biotech completed enrollment in its Phase 2 trial of IO102-IO103 with KEYTRUDA as a treatment given before and after surgery for resectable melanoma or head and neck cancer.

On February 4, the company published results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112, targeting arginase 1, which plays a key role in immune suppression.

In mid-March, IO Biotech was named to Fast Company’s list of the World’s Most Innovative Companies of 2025. The following month, the company presented new preclinical data for its lead candidate IO102-IO103 as well as IO170, which targets Transforming Growth Factor beta.

In its Q1 2025 financial results and business highlights released on May 14, IO Biotech shared that a readout of primary endpoint data from its pivotal Phase 3 trial of its lead investigational therapeutic cancer vaccine in patients with advanced melanoma is expected in the third quarter of 2025.

Shares of IO Biotech reached a year-to-date high of US$2.40 on July 28.

5. Spero Therapeutics (NASDAQ:SPRO)

Year-to-date gain: 110.95 percent
Market cap: US$124.12 million
Share price: US$2.22

Spero Therapeutics is developing novel treatments for rare diseases and multi-drug resistant bacterial infections with high unmet need. The company’s lead drug candidate is tebipenem pivoxil hydrobromide (HBr), a late-stage development asset developed in collaboration with pharma giant GSK (NYSE:GSK) to treat complicated urinary tract infections (cUTIs), including pyelonephritis.

Spero has an exclusive license agreement with GSK for the development and commercialization of the drug candidate in all ex-Asia markets. The FDA has granted tebipenem HBr qualified infectious disease product and fast track designations.

Shares in Spero traded below US$1.00 for much of the first half of 2025. However, the stock’s value surged 245 percent on May 28 to reach US$2.35 per share after Spero reported that its Phase 3 trial evaluating tebipenem HBr for treating cUTIs met its primary endpoint and stopped early for efficacy. GSK plans to include the findings in a filing to the FDA during H2.

Spero shares reached a year-to-date high of US$3.04 on July 9.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

(TheNewswire)

TORONTO, ON, August 13, 2025 TheNewswire – Silver Crown Royalties Inc. ( Cboe: SCRI,OTC:SLCRF; OTCQX: SLCRF; FRA: QS0) ( ‘Silver Crown’ or the ‘Company’ ) is pleased to announce that, further to its press release dated August 7, 2025, it has closed the acquisition of a royalty on 90% of the cash equivalent of silver produced each quarter from the past producing Scotia Mine (the ‘Silver Royalty’ ) with EDM Resources Inc. ( TSX-V: EDM; FSE: P3Z) ( ‘EDM’ ). The Silver Royalty provides for minimum of the cash equivalent of 7,000 ounces per year for 10 years starting at commercial production on the Scotia Mine. SCRi paid $250,000 in cash at closing and issued 60,000 units (‘ Units ‘) to EDM per Unit at a deemed value of C$10.00, with each Unit consisting of a common share in the capital of SCRi (‘ Common Share ‘) and one warrant exercisable into an additional Common Share at a price of C$13.00 for a period of 36 months following the date hereof. SCRi must pay EDM an additional C$250,000 cash payment following the date hereof as deferred consideration for the Silver Royalty.

ABOUT EDM RESOURCES INC.

EDM Resources Inc. (‘EDM’) ( TSX-V: EDM; FSE: P3Z) is a Canadian exploration and mining company that has full ownership of the Scotia Mine and related facilities near Halifax, Nova Scotia. Through its wholly owned subsidiary, EDM also holds several prospective exploration licenses near its Scotia Mine and in the surrounding regions of Nova Scotia .

ABOUT Silver Crown Royalties INC.

Founded by seasoned industry professionals, Silver Crown Royalties ( Cboe: SCRI | OTCQX: SLCRF | FRA: QS0) is a publicly traded silver royalty company dedicated to generating free cash flow. Silver Crown (SCRi) currently holds five silver royalties. Its business model offers investors exposure to precious metals, providing a natural hedge against currency devaluation while mitigating the adverse effects of production-related cost inflation. SCRi strives to minimize the economic burden on mining projects while simultaneously maximizing shareholder returns. For further information, please contact:

Silver Crown Royalties Inc.

Peter Bures, Chairman and CEO

Telephone: (416) 481-1744

Email: pbures@silvercrownroyalties.com

FORWARD-LOOKING STATEMENTS

This release contains certain ‘forward looking statements’ and certain ‘forward-looking information’ as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as ‘may’, ‘will’, ‘should’, ‘expect’, ‘intend’, ‘estimate’, ‘anticipate’, ‘believe’, ‘continue’, ‘plans’ or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements and information include, but are not limited to, SCRi must pay EDM an additional C$250,000 cash payment following the date hereof as deferred consideration for the Silver Royalty . Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual actions, events or results to be materially different from those expressed or implied by such forward-looking information, including but not limited to: the impact of general business and economic conditions; the absence of control over mining operations from which SCRi will purchase gold and other metals or from which it will receive royalty payments and risks related to those mining operations, including risks related to international operations, government and environmental regulation, delays in mine construction and operations, actual results of mining and current exploration activities, conclusions of economic evaluations and changes in project parameters as plans continue to be refined; accidents, equipment breakdowns, title matters, labor disputes or other unanticipated difficulties or interruptions in operations; SCRi’s ability to enter into definitive agreements and close proposed royalty transactions; the inherent uncertainties related to the valuations ascribed by SCRi to its royalty interests; problems inherent to the marketability of gold and other metals; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; industry conditions, including fluctuations in the price of the primary commodities mined at such operations, fluctuations in foreign exchange rates and fluctuations in interest rates; government entities interpreting existing tax legislation or enacting new tax legislation in a way which adversely affects SCRi; stock market volatility; regulatory restrictions; liability, competition, the potential impact of epidemics, pandemics or other public health crises on SCRi’s business, operations and financial condition, loss of key employees. SCRi has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. SCRi undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available.

This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities of the Company in Canada, the United States or any other jurisdiction. Any such offer to sell or solicitation of an offer to buy the securities described herein will be made only pursuant to subscription documentation between the Company and prospective purchasers. Any such offering will be made in reliance upon exemptions from the prospectus and registration requirements under applicable securities laws, pursuant to a subscription agreement to be entered into by the Company and prospective investors. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

CBOE CANADA DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Copyright (c) 2025 TheNewswire – All rights reserved.

News Provided by TheNewsWire via QuoteMedia

This post appeared first on investingnews.com